Health Technology

Daiichi Sankyo Co., Ltd.

Business Summary

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2023	JPY	USD
Revenue	1,278.47B	9,434.04M
Gross Profit	914,953M	6,751.55M
Operating income	102,162M	753.86M
Income before tax	126,873M	936.21M
Net income	109,188M	805.71M
EBITDA	169,951M	1,254.08M
Diluted EPS	56.91	0.42
Dividends Per Share	30	0.22
Total Assets	2,508.88B	18,851.07M
Total liabilities	1,063.03B	7,987.30M
Total equity	1,445.85B	10,863.73M
Operating cash flow	114,514M	845.01M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Revenue	929,717M	981,793M	962,516M	1,044.89B	1,278.47B
Gross Profit	565,112M	638,587M	624,227M	682,090M	914,953M
Operating income	90,461M	118,028M	80,179M	82,462M	102,162M
Income before tax	85,831M	141,164M	73,956M	73,387M	126,873M
Net income	93,410M	129,074M	75,957M	66,972M	109,188M
EBITDA	136,630M	170,639M	137,561M	150,181M	169,951M
Diluted EPS	47.95	66.26	39.11	34.90	56.91
Dividends Per Share	23.33	23.33	26.99	27	30
Total Assets	2,088.05B	2,105.61B	2,085.17B	2,221.40B	2,508.88B
Total liabilities	838,343M	791,549M	807,030M	864,865M	1,063.03B
Total equity	1,249.64B	1,305.80B	1,272.05B	1,350.87B	1,445.85B
Operating cash flow	92,033M	196,601M	192,207M	139,226M	114,514M

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Revenue	8,383.78M	9,029.99M	9,075.42M	9,298.45M	9,434.04M
Gross Profit	5,095.93M	5,873.37M	5,885.74M	6,069.89M	6,751.55M
Operating income	815.73M	1,085.55M	755.99M	733.82M	753.86M
Income before tax	773.98M	1,298.34M	697.32M	653.06M	936.21M
Net income	842.33M	1,187.15M	716.18M	595.98M	805.71M
EBITDA	1,232.07M	1,569.44M	1,297.04M	1,336.45M	1,254.08M
Diluted EPS	0.43	0.60	0.36	0.31	0.42
Dividends Per Share	0.21	0.21	0.25	0.24	0.22
Total Assets	18,864.80M	19,504.59M	18,870.38M	18,301.97M	18,851.07M
Total liabilities	7,574.13M	7,332.21M	7,303.43M	7,125.56M	7,987.30M
Total equity	11,290.07M	12,095.86M	11,511.79M	11,129.73M	10,863.73M
Operating cash flow	829.91M	1,808.22M	1,812.29M	1,238.96M	845.01M

Valuation Measures

Mar 2023
PER	84.66
ROA	4.61%
ROE	7.80%
Operating margin	7.99%
Profit margin	8.54%

Key executives

President, CEO & Representative Director: Sunao Manabe
CFO, Director & General Manager-Administration: Hiroyuki Okuzawa
Director & Chief Information Officer: Masahiko Ohtsuki
Global Director-Research & Development: Ken Takeshita
General Manager-Research & Development: Wataru Takasaki

Shareholders

Nomura Asset Management Co., Ltd. (5.1%)
Nippon Life Insurance Co. (4.4%)
Capital Research & Management Co. (World Investors) (4.3%)
Asset Management One Co., Ltd. (3.2%)
BlackRock Fund Advisors (2.7%)
The Vanguard Group, Inc. (2.5%)
Wellington Management Co. LLP (2.5%)
Nikko Asset Management Co., Ltd. (2.0%)
Daiwa Asset Management Co. Ltd. (2.0%)
Mizuho Bank Pension Fund (1.9%)

Contact Details

Website:http://www.daiichisankyo.co.jp
Address: Daiichi Sankyo Head Office Bldg, A&B, 3-5-1 Nihonbashi-honcho, Tokyo, 103-8426, Japan
Phone: +81.3.6225.1111

Related Companies

Daiichi Sankyo Chemical Pharma Co., Ltd.
Daiichi Sankyo RD Novare Co., Ltd.
Daiichi Sankyo Biotech Co. Ltd.
Astellas Pharma, Inc. /3 Drug Products/
Daiichi Sankyo Belgium SA
Daiichi Sankyo Restricted Stock Compensation Plan
Daiichi Sankyo Pharma, Inc.
Novare Co. Ltd.
Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.
Daiichi Sankyo Venezuela SA
Daiichi Sankyo (Schweiz) AG
Daiichi Sankyo Hong Kong Ltd.
Daiichi Forging Dalian Co. Ltd.
Kitasato Daiichi Sankyo Vaccine Co., Ltd.
Daiichi Sankyo Pension Fund
Daiichi Sankyo Espha Co., Ltd.
Daiichi Sankyo (Thailand) Ltd.
Daiichi Sankyo Employee Stock Ownership Plan
Daiichi Sankyo (China) Holdings Co., Ltd.
Daiichi Sankyo Ireland Ltd.
Sankyo Pharma Nederland BV
Daiichi Sankyo Taiwan Ltd.
NV Sankyo Pharma Belgium SA
Daiichi Sankyo Portugal, Unipessoal, Lda.
Daiichi Sankyo Austria GmbH
Daiichi Sankyo Nederland BV
Daiichi Sankyo Logistics Co. Ltd.
Daiichi Sankyo Italia SpA
U3 Pharma GmbH
Daiichi Sankyo Deutschland GmbH

Competitors

AstraZeneca PLC
Boryung Corporation
Hanmi Pharmaceutical Co., Ltd.
LegoChem Biosciences, Inc.
ImmunoGen, Inc.
Zymeworks Inc.
Zymeworks Inc.
Biomea Fusion Inc
NeuroBo Pharmaceuticals, Inc.
Aprea Therapeutics, Inc.
Springworks Therapeutics, Inc.
Allogene Therapeutics, Inc.
IGM Biosciences, Inc.
Sutro Biopharma, Inc.
Bolt Biotherapeutics, Inc.
Reata Pharmaceuticals, Inc. Class A
Aileron Therapeutics, Inc.
Ambrx Biopharma, Inc. Sponsored ADR
CytomX Therapeutics, Inc.
Oncorus, Inc.
Blueprint Medicines Corp.
MacroGenics, Inc.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A
ADC Therapeutics Ltd
ALTEOGEN Inc.
PTC Therapeutics, Inc.
Nuvation Bio, Inc. Class A
Defence Therapeutics Inc Class A
Iovance Biotherapeutics Inc
Janux Therapeutics, Inc.

Last Updated on 9 Jun, 2023